- Home
- BIRD vs ECOR Comparison
BIRD vs ECOR Comparison
Compare BIRD & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIRD
- ECOR
- Stock Information
- Founded
- BIRD 2015
- ECOR 2005
- Country
- BIRD United States
- ECOR United States
- Employees
- BIRD N/A
- ECOR N/A
- Industry
- BIRD Apparel
- ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- BIRD Consumer Discretionary
- ECOR Health Care
- Exchange
- BIRD Nasdaq
- ECOR Nasdaq
- Market Cap
- BIRD 50.7M
- ECOR 57.5M
- IPO Year
- BIRD 2021
- ECOR 2018
- Fundamental
- Price
- BIRD $6.56
- ECOR $6.24
- Analyst Decision
- BIRD Hold
- ECOR Strong Buy
- Analyst Count
- BIRD 2
- ECOR 2
- Target Price
- BIRD $11.00
- ECOR $25.50
- AVG Volume (30 Days)
- BIRD 52.3K
- ECOR 213.2K
- Earning Date
- BIRD 03-11-2025
- ECOR 03-12-2025
- Dividend Yield
- BIRD N/A
- ECOR N/A
- EPS Growth
- BIRD N/A
- ECOR N/A
- EPS
- BIRD N/A
- ECOR N/A
- Revenue
- BIRD $189,757,000.00
- ECOR $25,182,000.00
- Revenue This Year
- BIRD N/A
- ECOR $40.88
- Revenue Next Year
- BIRD $6.73
- ECOR $48.01
- P/E Ratio
- BIRD N/A
- ECOR N/A
- Revenue Growth
- BIRD N/A
- ECOR 57.09
- 52 Week Low
- BIRD $5.07
- ECOR $5.32
- 52 Week High
- BIRD $18.34
- ECOR $19.49
- Technical
- Relative Strength Index (RSI)
- BIRD 57.95
- ECOR 18.84
- Support Level
- BIRD $5.86
- ECOR $6.32
- Resistance Level
- BIRD $6.18
- ECOR $7.05
- Average True Range (ATR)
- BIRD 0.33
- ECOR 0.82
- MACD
- BIRD 0.15
- ECOR -0.08
- Stochastic Oscillator
- BIRD 99.30
- ECOR 5.91
About BIRD Allbirds Inc.
Allbirds Inc is a lifestyle brand that innovates with naturally derived materials to make footwear and apparel products in a better way, while treading lighter on the planet. Its primary source of revenue is from sales of shoes and apparel products. The majority of the revenue is derived from United States.
About ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.